Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

LX1606 Hippurate

HY-13055

(Telotristat etiprate; LX 1606 Hippurate; LX-1606 Hippurate)

LX1606 Hippurate

LX1606 Hippurate Chemical Structure

LX1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity.

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $199 In-stock
5 mg $130 In-stock
10 mg $240 In-stock
50 mg $800 In-stock
100 mg $1400 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO €195 In-stock
5 mg €127 In-stock
10 mg €235 In-stock
50 mg €784 In-stock
100 mg €1372 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: LX1606 Hippurate
Cat. No.: HY-13055

LX1606 Hippurate Data Sheet

  • View current batch:

    Purity: 99.76%%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

Related Compound Libraries

Biological Activity of LX1606 Hippurate

LX1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity.
IC50 Value:
Target: Tryptophan hydroxylase
in vitro:
in vivo: LX1606 (LX 1606, LX-1606) is useful for Neurological Diseas [1]. LX1606 were given orally to mice. LX1606 reduced 5-HT significantly in the gut and blood but not in the brain. oral LX1032 reduced the severity of TNBS-induced colitis; the expression of 24% of 84 genes encoding inflammation-related cytokines and chemokines was lowered at least fourfold and the reduced expression of 17% was statistically significant [1]. Treatment with LX1606 showed a strong positive effect in ameliorating TNBS-induced IBD in mice as assessed by various parameters of disease development. These preclinical data demonstrate that inhibition of TPH activity by LX1606 may provide a new approach for the treatment of IBD and its serotonin-mediated symptoms[3].
 

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 754.15 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C36H35ClF3N7O6
CAS No 1137608-69-5
Solvent & Solubility

DMSO:28mg/mL

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 1.3260 mL 6.6300 mL 13.2600 mL
5 mM 0.2652 mL 1.3260 mL 2.6520 mL
10 mM 0.1326 mL 0.6630 mL 1.3260 mL

Clinical Information of LX1606 Hippurate

Product Name Sponsor Only Condition Start Date End Date Phase Last Change Date
LX1606 Hippurate Lexicon Pharmaceuticals Inc 31-AUG-13 Phase 1 24-OCT-13
Lexicon Pharmaceuticals Inc Ulcerative colitis 31-DEC-11 31-AUG-13 Phase 2 24-OCT-13
Lexicon Pharmaceuticals Inc Carcinoid syndrome 31-MAY-10 Phase 2 12-NOV-13
Lexicon Pharmaceuticals Inc Carcinoid syndrome 31-OCT-12 30-APR-15 Phase 3 30-OCT-13
Lexicon Pharmaceuticals Inc Carcinoid syndrome 31-MAR-09 31-DEC-13 Phase 2 11-NOV-13

References on LX1606 Hippurate

Other Forms

Inhibitor Kit